← All trials
NCT05783622
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2023
- Primary completion
- Jan 31, 2026
- Completion date
- Oct 31, 2027
- First posted
- Mar 24, 2023
- Last posted
- Dec 12, 2023
- Enrollment
- 130
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Janux TherapeuticsLead sponsor
- Janux TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.